PharmiWeb Today Story
- Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1
- This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2
- The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selection
Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumour.
“With an unprecedented 76% reduction in the risk of disease recurrence or death versus chemotherapy, Alecensa significantly improves upon the standard of care for people with early-stage ALK-positive lung cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At Roche, our goal is to give patients the best chance of cure by bringing effective, targeted treatments to early-stage disease befor…
Read More...Articles
What Does a Clinical SAS Programmer Do?
16-Apr-2024
The Evolution of Clinical Data Management
10-Apr-2024
9 Clinical Data Management Career Paths
08-Apr-2024
Featured Events
-
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021 -
UK Clinical Research: A Professional Awareness Upd…
26-Jan-2022 - 27-Jan-2022 -
Pharmaceutical Manufacturing and Packaging Congres…
20-Jun-2022 - 21-Jun-2022 -
PM Society: Measuring Patient Engagement: Opening…
12-Oct-2022 - 12-Oct-2022 -
Finding the Value in Strategic Outsourcing Partner…
22-Feb-2023 - 22-Feb-2023 -
Mastering Launch Excellence
28-Mar-2023 - 30-Mar-2023
News
-
Xlife Sciences AG Publishes 2023 Annual Report
23-Apr-2024 -
MindBio Landmark Sleep Research Published in Prest…
23-Apr-2024 -
Applied DNA Announces 1-For-20 Reverse Stock Split…
22-Apr-2024 -
Alliance Spine and Pain Centers Implement Behavior…
22-Apr-2024 -
Cloud DX Will Report Fiscal Year 2023 Results and…
22-Apr-2024 -
Viromed Medical AG reaches important milestone – a…
22-Apr-2024